185 related articles for article (PubMed ID: 20920292)
1. Clinical significance of Polycomb gene expression in brain tumors.
Crea F; Hurt EM; Farrar WL
Mol Cancer; 2010 Sep; 9():265. PubMed ID: 20920292
[TBL] [Abstract][Full Text] [Related]
2. FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells.
Du J; Li L; Ou Z; Kong C; Zhang Y; Dong Z; Zhu S; Jiang H; Shao Z; Huang B; Lu J
Breast Cancer Res Treat; 2012 Jan; 131(1):65-73. PubMed ID: 21465172
[TBL] [Abstract][Full Text] [Related]
3. BMI1 sustains human glioblastoma multiforme stem cell renewal.
Abdouh M; Facchino S; Chatoo W; Balasingam V; Ferreira J; Bernier G
J Neurosci; 2009 Jul; 29(28):8884-96. PubMed ID: 19605626
[TBL] [Abstract][Full Text] [Related]
4. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
5. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
6. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
8. A novel repressive E2F6 complex containing the polycomb group protein, EPC1, that interacts with EZH2 in a proliferation-specific manner.
Attwooll C; Oddi S; Cartwright P; Prosperini E; Agger K; Steensgaard P; Wagener C; Sardet C; Moroni MC; Helin K
J Biol Chem; 2005 Jan; 280(2):1199-208. PubMed ID: 15536069
[TBL] [Abstract][Full Text] [Related]
9. Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM
Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826
[TBL] [Abstract][Full Text] [Related]
10. The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors.
Bommi PV; Dimri M; Sahasrabuddhe AA; Khandekar J; Dimri GP
Cell Cycle; 2010 Jul; 9(13):2663-73. PubMed ID: 20543557
[TBL] [Abstract][Full Text] [Related]
11. The polycomb repressive complex 2 is a potential target of SUMO modifications.
Riising EM; Boggio R; Chiocca S; Helin K; Pasini D
PLoS One; 2008 Jul; 3(7):e2704. PubMed ID: 18628979
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
[TBL] [Abstract][Full Text] [Related]
13. EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor.
Hwang C; Giri VN; Wilkinson JC; Wright CW; Wilkinson AS; Cooney KA; Duckett CS
Breast Cancer Res Treat; 2008 Jan; 107(2):235-42. PubMed ID: 17453341
[TBL] [Abstract][Full Text] [Related]
14. The E2F6 Transcription Factor is Associated with the Mammalian SUZ12-Containing Polycomb Complex.
Shirahama Y; Yamamoto K
Kurume Med J; 2023 Feb; 67(4):171-183. PubMed ID: 36464274
[TBL] [Abstract][Full Text] [Related]
15. Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes.
Sewalt RG; van der Vlag J; Gunster MJ; Hamer KM; den Blaauwen JL; Satijn DP; Hendrix T; van Driel R; Otte AP
Mol Cell Biol; 1998 Jun; 18(6):3586-95. PubMed ID: 9584199
[TBL] [Abstract][Full Text] [Related]
16. The Polycomb group protein EZH2 directly controls DNA methylation.
Viré E; Brenner C; Deplus R; Blanchon L; Fraga M; Didelot C; Morey L; Van Eynde A; Bernard D; Vanderwinden JM; Bollen M; Esteller M; Di Croce L; de Launoit Y; Fuks F
Nature; 2006 Feb; 439(7078):871-4. PubMed ID: 16357870
[TBL] [Abstract][Full Text] [Related]
17. EZH2 and cancer stem cells: fact or fiction?
Crea F
Epigenomics; 2011 Apr; 3(2):127-8. PubMed ID: 22122274
[No Abstract] [Full Text] [Related]
18. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.
Hoffmann MJ; Engers R; Florl AR; Otte AP; Muller M; Schulz WA
Cancer Biol Ther; 2007 Sep; 6(9):1403-12. PubMed ID: 18637271
[TBL] [Abstract][Full Text] [Related]
19. Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells.
Mochizuki-Kashio M; Mishima Y; Miyagi S; Negishi M; Saraya A; Konuma T; Shinga J; Koseki H; Iwama A
Blood; 2011 Dec; 118(25):6553-61. PubMed ID: 22042701
[TBL] [Abstract][Full Text] [Related]
20. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H; Cai Q; Godwin AK; Zhang R
Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
